Panasonic TV to Skyworth 📺 BYD Charger 3x Tesla ⚡ Electric Ships Go Cargo 🚢

In partnership with

2026-03-02 | subscribe | homepage

Welcome back to China Insights Weekly. Here are some of the key highlights for this week’s edition:

• China targets 70% chip tool localization by 2027, 28nm systems near mass use

• Clean power capacity overtakes fossil fuels, solar up 1,500% in a decade

• Global pharma giants ink billion-dollar China deals, siRNA and GLP-1 expand

• Humanoid robotics gets national standards, 330 models released in one year

Remember to follow us on LinkedIn, X or Facebook.

🚀 Headlines

Japan’s Panasonic transfers its US and European TV business to China’s Skyworth (link)

Panasonic has partnered with China’s Skyworth Group to transfer its North American and European TV sales, marketing, logistics, and manufacturing operations to Skyworth starting April 2026. Panasonic retains brand ownership and quality control while focusing on high-end models in Japan; Skyworth, the world’s third-largest OLED TV manufacturer, assumes operational control to cut costs and improve profitability. The deal includes joint development of premium OLED TVs. It targets a double-digit market share in Europe, marking another Japanese electronics giant ceding TV operations to Chinese manufacturers following similar moves by Sony, Sharp, and Toshiba.

China's Frontier Biotech agrees to 1 billion siRNA therapy deal with UK’s GSK, Pfizer signs USD 495 million Sciwind’s weight-loss drug deal (link, link)

Frontier Biotechnologies signed an agreement with UK pharmaceutical giant GSK on February 16. GSK secured exclusive global rights to develop and commercialize two siRNA therapies in a deal valued at over USD1 billion. The financial structure includes a USD40 million upfront payment, USD13 million in near-term milestones, and up to USD950 million in development and commercialization milestones, plus royalties. Nanjing-based Frontier will advance Phase I trials and investigational new drug (IND) applications in China for the two drugs, one currently in the IND stage and one preclinical, while GSK leads subsequent global development and commercialization. The agreement provides Frontier with substantial cash flow and validates its siRNA technology platform internationally.

Pfizer has secured exclusive commercialization rights in China for ecnoglutide, a GLP-1 weight-loss drug developed by Hangzhou-based Sciwind Biosciences, in a deal valued at up to USD 495 million comprising an upfront payment plus regulatory and sales-based milestones. Ecnoglutide received approval for type 2 diabetes treatment in January, with its application for long-term weight management currently under review by Chinese regulators. The agreement targets China's expanding obesity market, where 14.1% of adults are classified as obese, amid intensifying competition that includes five approved GLP-1 drugs, Novo Nordisk's semaglutide and Eli Lilly's tirzepatide, which triggered a price war late last year with respective cuts of 50% and 80%. Sciwind has separately licensed rights to South Korea's HK Inno.N and UK's Verdiva for markets outside China.

Nike-backed ACG opens 1st global store in Beijing amid China sportswear surge (link)

Nike-backed All Conditions Gear (ACG) has opened its first global brand store in Beijing’s upscale Sanlitun district, operated directly by Nike to capture China’s surging outdoor sports market. The move follows entries by Norway’s Norrøna, the UK’s Soar, and Canada’s Ciele Athletics last year, with Topsports International Holdings serving as the exclusive operating partner for the three brands in China. Topsports also launched Ektos, a running brand collection store featuring these labels. According to Authentic Brands Group, 70% of its portfolio focuses on outdoor sports. Nike’s China revenue remains roughly one-third of its North America sales, and significant expansion potential exists as consumer demand shifts toward higher-priced, specialized gear and as lower-tier cities present growth opportunities.

China ramps up chip tool push, sets 70% target by 2027 (link)

China has set a target to achieve 70% localization of semiconductor equipment for mature process technologies by 2027, up from current mandates requiring chipmakers to source over 50% of equipment domestically when expanding production capacity. The push, driven by U.S. sanctions and supply chain security concerns, is led by domestic champions SMEE, NAURA Technology Group, and AMEC. SMEE has advanced its 28nm ArF immersion lithography systems to the verification stage, while NAURA has initiated mass production of 28nm etching tools, and AMEC is verifying 14nm equipment. Additionally, China has reportedly assembled an EUV prototype using components from older ASML systems, targeting functional chip production by 2028. Industry reports indicate validation cycles for domestic equipment are being completed in approximately one year.

China's epic renewables boom lifts it into rare clean capacity club (link)

China achieved a historic energy transition milestone in 2025, deploying 1,494 gigawatts of clean power capacity, surpassing fossil fuel capacity (1,420 GW) for the first time by a margin of 73 GW. Clean sources now comprise 51% of China's power fleet, placing it alongside Brazil, France, and Germany as major economies powered mainly by clean energy. The transformation was driven by a 1,554% surge in utility-scale solar capacity since 2015, which expanded from 2.4% to 18.3% of operational capacity while coal's share dropped from 64% to a record low of 42.7%. Overall clean capacity expanded 253% between 2015 and 2025, compared to 50% growth in fossil fuel generation capacity, yielding a 113% rise in total power generation capacity over the decade.